Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business Highlights – PACE-1 trial of ALTO-207 in treatment-resistant depression (TRD) on track; topline data in 2H 2027 – – Phase 1 study results on the modified-release formulation of ALTO-20

Event · Earnings
Original reporting
Published Nov 10, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ANRO
Bullish
high confidence
Mentioned
$ANRO
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ANROBullishMed
01

Why it matters

The $100 M direct offering strengthens the balance sheet, extending cash runway to 2030 and supporting upcoming Phase 3 trials.

02

Market read

First‑report of quarterly results and financing provides fresh data for traders; likely influences ANRO price in the short term.

03

What to watch

Upcoming FDA interactions and trial data releases could dominate price action later in 2027.

Relevance 7/10Novelty 8/10Timing: after‑hours filing
AlphAI · Earnings readANRO · Q3 2026 · ended 2026-09-30

Alto Neuroscience reports Q3 2026 net loss of $25.1 million, up from $14.2 million, with R&D up to $18.2 million; cash of $319.8 million expected to fund operations through 2030

→Mixed quarter

The filing reports no revenue. Operating costs and the net loss rose sharply year over year as the ALTO-207 PACE program and headcount expanded. Balance sheet strength improved after a $100.0 million July 2026 financing, and the company reiterated its pipeline milestone timing. The filing contains no financial guidance, so the read rests on spending growth, cash runway and milestone delivery.

EPS · GAAP
$(0.54)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, Q3 2026GAAP$18.2 million (Q3 2026); $18,161 thousand in statement of operations––
General and administrative expenses, Q3 2026GAAP$9.1 million (Q3 2026); $9,064 thousand in statement of operations––
Total operating expenses, Q3 2026GAAP$27.23M––
Loss from operations, Q3 2026GAAP−$27.23M––
Interest income, Q3 2026GAAP$2.6M––
Interest expense, Q3 2026GAAP−$463K––
Other, net, Q3 2026GAAP−$36K––
Total other income, net, Q3 2026GAAP$2.10M––
Net loss, Q3 2026GAAP$(25.1) million; $(25,124) thousand in statement of operations––
Comprehensive loss, Q3 2026GAAP−$25.12M––
Net loss per share, basic and diluted, Q3 2026GAAP$(0.54)––
Research and development expenses, nine months 2026GAAP$60.56M––
General and administrative expenses, nine months 2026GAAP$22.93M––
Total operating expenses, nine months 2026GAAP$83.49M––
Loss from operations, nine months 2026GAAP−$83.49M––
Interest income, nine months 2026GAAP$6.27M––
Interest expense, nine months 2026GAAP−$1.50M––
Loss on debt extinguishment, nine months 2026GAAP— (no amount printed for 2026)––
Other, net, nine months 2026GAAP−$281K––
Total other income, net, nine months 2026GAAP$4.49M––
Net loss, nine months 2026GAAP−$79.00M––
Comprehensive loss, nine months 2026GAAP−$79.00M––
Net loss per share, basic and diluted, nine months 2026GAAP$(1.87)––
Cash, cash equivalents and restricted cash, September 30, 2026GAAP$319.8 million; $319,844 thousand––
Total assets, September 30, 2026GAAP$326.5M––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • July 2026 underwritten registered direct offering of 3,776,436 shares of common stock at $26.48 per share, gross proceeds of $100.0 million and net proceeds of approximately $94.6 million. Proceeds are intended to accelerate and expand ALTO-207 development, including PACE-3, and for general working capital.

What drove it

  • Company states the R&D increase was primarily driven by costs associated with the ALTO-207 PACE program.
  • Company states the G&A increase was primarily due to increased headcount and related personnel costs.
  • Company states the increase in cash since December 31, 2025 follows the $100 million financing completed in July 2026.
  • Interest income rose to $2,600 thousand from $1,532 thousand in Q3 2026 versus Q3 2025, as printed; the filing does not state a cause.

Concerns

  • Net loss widened to $25.1 million from $14.2 million, and nine-month net loss reached $(78,999) thousand versus $(47,056) thousand.
  • Operating expenses rose in both the quarter and the nine months, with R&D and G&A both up year over year.
  • Net loss per share is $(0.54) versus $(0.52) in the prior year quarter, while weighted-average shares rose to 46,531 thousand from 27,104 thousand, reflecting the July 2026 offering.
  • Milestone timing is largely in 2027. PACE-1 topline is expected in 2H 2027, and the FDA interaction outcome and Phase 1 data are expected in late 2026 or early 2027 and remain subject to FDA feedback.
  • The filing states that trials may have unsatisfactory outcomes and that the company's cash runway projections may prove inaccurate, as listed among its forward-looking risk factors.

What to watch

  • Outcome of the ALTO-207 FDA interaction and Phase 1 modified-release formulation data, expected late 2026 or early 2027.
  • Initiation of the PACE-2 Phase 3 adjunctive TRD trial, expected early 2027 pending FDA alignment on design.
  • ALTO-300 Phase 2b MDD topline data, expected 1H 2027, and ALTO-100 Phase 2b BPD topline data, expected mid-2027.
  • PACE-1 Phase 2b adjunctive TRD topline data, expected 2H 2027, and PACE-3 Phase 3 monotherapy initiation, expected 2H 2027.
  • Trajectory of R&D and G&A expense in coming quarters, and whether the company's expectation of funding operations through 2030 holds.

Balance sheet and cash flow

  • Cash, cash equivalents and restricted cash: $319.8 million (September 30, 2026) versus $177.0 million (December 31, 2025) as reported.
  • Total assets: $326,505 thousand (September 30, 2026) versus $184,689 thousand (December 31, 2025).
  • Total liabilities: $29,975 thousand (September 30, 2026) versus $33,547 thousand (December 31, 2025).
  • Accumulated deficit: $(280,633) thousand (September 30, 2026) versus $(201,634) thousand (December 31, 2025).
  • The company expects its cash to fund planned operations through 2030. No operating or free cash flow figures are reported.

Analysis

Alto Neuroscience reported no revenue for the quarter ended September 30, 2026. The results are a function of development spending. Research and development expenses were $18.2 million versus $10.5 million a year earlier, and general and administrative expenses were $9.1 million versus $4.4 million. The company attributes the R&D increase primarily to costs of the ALTO-207 PACE program and the G&A increase primarily to higher headcount and related personnel costs. Total operating expenses were $27,225 thousand against $14,951 thousand, and the loss from operations followed the same path. Net loss reached $25.1 million versus $14.2 million, and net loss per share was $(0.54) versus $(0.52). Net other income of $2,101 thousand, which includes interest income of $2,600 thousand, partly offset the operating loss but did not change its direction.

For the nine months, research and development expenses were $60,563 thousand versus $33,623 thousand and general and administrative expenses were $22,929 thousand versus $15,686 thousand. The nine-month net loss was $(78,999) thousand against $(47,056) thousand, and nine-month net loss per share was $(1.87) versus $(1.74). The step-up in spending is therefore present across the year to date, not only in the quarter.

The balance sheet changed materially in 2026. Cash, cash equivalents and restricted cash rose to $319.8 million at September 30, 2026 from $177.0 million at December 31, 2025, after the July 2026 registered direct offering of 3,776,436 shares at $26.48 per share, which generated gross proceeds of $100.0 million and net proceeds of approximately $94.6 million. Total assets were $326,505 thousand and total liabilities were $29,975 thousand. The accumulated deficit increased to $(280,633) thousand from $(201,634) thousand. Management states that cash is expected to fund planned operations through 2030. The filing gives no operating or free cash flow figures, so the runway claim cannot be tested against cash generation in the document.

Operationally, the filing emphasizes timing. ALTO-207 PACE-1 topline data are expected in 2H 2027, PACE-2 is planned to start in early 2027 pending FDA alignment, and PACE-3 is expected to start in 2H 2027. ALTO-300 and ALTO-100 Phase 2b topline data are expected in 1H 2027 and mid-2027. The filing describes the Phase 1 modified-release formulation results and blinded PACE-1 safety data as expected by early 2027, with the FDA interaction outcome to follow. Forward-looking statements caution that trial outcomes may be unsatisfactory and that spending needs may exceed current plans. The filing contains no financial guidance, so there is no prior outlook to compare against this quarter.

Management, verbatim

PACE-1 remains on track, and our recent financing has enabled us to expand the ALTO-207 Phase 3 development plans to include both monotherapy and adjunctive trials, aimed at supporting a broad label in TRD.

Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience

Not in the filing

stated, not guessed
  • Revenue: the filing reports no revenue line; none is available for any period.
  • Gross margin, cost of sales and tax rate: not reported in the filing.
  • Financial guidance for 2026 or later periods: not provided in this filing.
  • Previous release outlook: not provided, so vs_prior_guidance cannot be assessed.
  • Prior-year and prior-quarter percentage changes for operating expense, loss and per-share lines: the filing does not print them.
  • Prior-year comparison for cash, cash equivalents and restricted cash and total assets: the only comparator printed is December 31, 2025, not the same period of the prior year.
  • Operating cash flow, investing cash flow and free cash flow: not reported.
  • Total equity: not printed; only total assets, total liabilities and accumulated deficit are given.
  • Share repurchases and dividends: none reported.
  • Segment information: none reported; the company presents a single business.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Alto Neuroscience is a NYSE‑listed clinical‑stage company developing ALTO‑207 for treatment‑resistant depression.

Company-level read

Ticker impact

$ANROBullishHigh confidence
Context

Alto Neuroscience filed an 8‑K reporting Q3 2026 results, a $100 M financing and cash runway through 2030.

Expected impact

potential upside as investors price in stronger balance sheet

Evidence & confidence

First‑report of a sizable capital raise and improved cash balance for a clinical‑stage biotech.

Market effects

May boost sentiment in the neuro‑psychiatric biotech sector as financing signals confidence.

Limited to US biotech investors; no broader regional effect.

Minimal global impact beyond sector peers.

Counterpoint

Financing could dilute existing shareholders and may not translate into near‑term clinical milestones.

Key entities

  • Alto Neuroscience, Inc.

    Clinical‑stage biopharma focused on neuropsychiatric disorders.

  • Amit Etkin, MD PhD

    Founder and CEO of Alto Neuroscience.

Every ANRO earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$ANROMed

H.C. Wainwright reiterates Alto Neuroscience stock rating at buy

H.C. Wainwright reiterated a Buy rating on Alto Neuroscience (ANRO) with a $60 price target. The stock is up 119% over the past year, trading at $31.15. The company reported Q3 2026 results, maintaining its 2027 Phase 2b readout timeline and 2030 cash runway. ALTO-207 trial results and FDA feedback are expected in late 2026 or early 2027. H.C. Wainwright raised its success probability for ALTO-207 to 40% and assigned a 5% probability to ALTO-203.

$ANROMed

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights – ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoin

$ANROMed

Alto Neuroscience, Inc. (ANRO): Results of Operations and Financial Condition

Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001999480 0001999480 2026-07-13 2026-07-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

$SUNEMed

SUNATION ENERGY ANNOUNCES THIRD QUARTER 2026 RESULTS; REPORTS SEQUENTIAL REVENUE AND GROSS MARGIN IMPROVEMENT AND PROVIDES SUNIVA MERGER UPDATE

SUNation Energy, Inc. (SUNE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SUNATION ENERGY ANNOUNCES THIRD QUARTER 2026 RESULTS; REPORTS SEQUENTIAL REVENUE AND GROSS MARGIN IMPROVEMENT AND PROVIDES SUNIVA MERGER UPDATE Third-quarter revenue of $11.2 million increased from $8.2 million in the second quarter; year-over-year results continued

$TRUGMed

TruGolf Reports Top Third Quarter Results

TruGolf Holdings, Inc. (TRUG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 TruGolf Reports Top Third Quarter Results Third Quarter Revenue Up 29.4% Year-over-Year to $5.3 Million Salt Lake City, Utah, November 16, 2026 - TruGolf Holdings, Inc. (NASDAQ: TRUG), the owner of TruGolf, a leading provider of golf simulator software and hardware,